Biogen (BIIB) Total Liabilities (2009 - 2026)

Biogen (BIIB) has reported Total Liabilities for 18 consecutive years, with $10.8 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 2.02% year-over-year to $10.8 billion; the TTM figure through Mar 2026 stood at $10.8 billion (down 2.02% YoY), while the FY2025 annual figure was $11.2 billion, down 1.33% from the prior year.
• Total Liabilities came in at $10.8 billion for Q1 2026 at Biogen, down from $11.2 billion in the prior quarter.
• The five-year high for Total Liabilities was $13.7 billion in Q3 2023, with the low at $10.7 billion in Q2 2025.
• Average Total Liabilities over 5 years is $11.6 billion, with a median of $11.2 billion recorded in 2025.
• The largest YoY upside for Total Liabilities was 13.45% in 2023 against a maximum downside of 19.08% in 2023.
• Year by year, Total Liabilities stood at $11.2 billion in 2022, then increased by 7.88% to $12.0 billion in 2023, then slipped by 5.91% to $11.3 billion in 2024, then retreated by 1.33% to $11.2 billion in 2025, then slipped by 3.14% to $10.8 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $10.8 billion, $11.2 billion, and $11.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.